SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
CADENCE PHARMACEUTICALS
(NQNM:CADX Last Sale: 5.51 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (CADX : $5.51)
$278 million Market Cap at September 12, 2013
Employs 43.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
12481 High Bluff Drive Research Report Earnings Snapshot - Last 02/28/18
San Diego, CA 92130 Fact Sheet
Phone: 858-436-1400 Financial Statements
Peer Comparison
Annual Reports

Cam L. Garner, Co-Founder/Chmn., David Socks, Co-Founder, Theodore R. Schroeder, Pres./CEO, William R. LaRue, CFO
IPO at $9 October 24, 2006. Raised $54 million, selling 6 million shares, 21% of the outstanding. Lead Manager: Merrill Lynch. Announced that pain drug candidate failed to meet the main goal of a late-stage trial January 11, 2008.
Historical Charts    Technical Analysis
No Historical Data available for CADX

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common CADX $5.51 $ 0 $5.4 $5.6 357,086 $2.88 $8.26 50,403
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $277,721

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex